379 Efficacy of spesolimab in patients with generalized pustular psoriasis (GPP) flares with and without systemic inflammation

This subgroup analysis of the Effisayil 1 trial (NCT03782792) compared patient characteristics and assessed effects spesolimab in patients with a GPP flare with/without baseline systemic inflammation. Patients were randomised 2:1 to single infusion IV 900 mg or placebo. Systemic inflammation at was defined as elevated CRP (>ULN 10 mg/L) neutrophil count (>ULN, 7.23x109/L). GPPGA pustulation subscore 0 (primary endpoint) total score 0/1 (key secondary Week 1. Missing values any use other medication for regarded non-response. Among available data, 33 48 had >ULN 30 49 neutrophils >ULN; 23 both. At baseline, higher median GPPASI scores (30.8) vs those ≤ULN (15.1) percentage hospitalised current (61% 20%); lower FACIT-fatigue also observed In all subgroups, more achieved primary endpoint after receiving placebo; each subgroup, results (spesolimab placebo) were: (55.0% 7.7%); (41.7% 0%); (60.0% (53.8% 16.7%). Key data consistent. extensive severe skin lesions than without; rapid pustular clearance placebo, irrespective